- Recommendation ID
- TA287/1
- Question
- There have been no head-to-head trials of rivaroxaban compared with a low molecular weight heparin for people who have cancer and experience an acute pulmonary embolism or deep vein thrombosis. As in NICE technology appraisal guidance 261 it is recommended that further research should be carried out.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
- Number
- TA287
- Date issued
- June 2013
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 15/07/2013 |